Everest Medicines Future Growth
Future criteria checks 5/6
Everest Medicines is forecast to grow earnings and revenue by 76.3% and 37.8% per annum respectively. EPS is expected to grow by 76.7% per annum. Return on equity is forecast to be 1.3% in 3 years.
Key information
76.3%
Earnings growth rate
76.7%
EPS growth rate
Biotechs earnings growth | 33.7% |
Revenue growth rate | 37.8% |
Future return on equity | 1.3% |
Analyst coverage | Low |
Last updated | 26 Jul 2024 |
Recent future growth updates
Recent updates
Does Everest Medicines (HKG:1952) Have A Healthy Balance Sheet?
Apr 27Everest Medicines Limited (HKG:1952) Annual Results: Here's What Analysts Are Forecasting For This Year
Mar 31A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)
Jan 31A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)
Sep 26Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 2,073 | 33 | -229 | N/A | 3 |
12/31/2025 | 1,438 | -160 | -317 | -198 | 5 |
12/31/2024 | 670 | -646 | -1,214 | -862 | 5 |
12/31/2023 | 126 | -844 | 545 | -769 | N/A |
9/30/2023 | 73 | -424 | 610 | -925 | N/A |
6/30/2023 | 21 | -3 | 675 | -1,082 | N/A |
3/31/2023 | 17 | -125 | -174 | -1,119 | N/A |
12/31/2022 | 13 | -247 | -1,024 | -1,156 | N/A |
9/30/2022 | 7 | -770 | -1,479 | -1,006 | N/A |
6/30/2022 | 1 | -1,294 | -1,934 | -857 | N/A |
3/31/2022 | 1 | -1,151 | -1,820 | -793 | N/A |
12/31/2021 | 0 | -1,009 | -1,706 | -730 | N/A |
9/30/2021 | 0 | -3,213 | -1,238 | -685 | N/A |
6/30/2021 | N/A | -5,418 | -770 | -640 | N/A |
3/31/2021 | N/A | -6,154 | -1,092 | -582 | N/A |
12/31/2020 | N/A | -5,658 | -992 | -472 | N/A |
3/31/2020 | N/A | -10 | -271 | -126 | N/A |
12/31/2019 | N/A | -215 | -182 | -89 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1952 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: 1952 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 1952 is expected to become profitable in the next 3 years.
Revenue vs Market: 1952's revenue (37.8% per year) is forecast to grow faster than the Hong Kong market (7.4% per year).
High Growth Revenue: 1952's revenue (37.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1952's Return on Equity is forecast to be low in 3 years time (1.3%).